498 related articles for article (PubMed ID: 33112126)
1. Targeting Crucial Host Factors of SARS-CoV-2.
Tharappel AM; Samrat SK; Li Z; Li H
ACS Infect Dis; 2020 Nov; 6(11):2844-2865. PubMed ID: 33112126
[TBL] [Abstract][Full Text] [Related]
2. Molecular Basis of Pathogenesis of Coronaviruses: A Comparative Genomics Approach to Planetary Health to Prevent Zoonotic Outbreaks in the 21st Century.
Asrani P; Hasan GM; Sohal SS; Hassan MI
OMICS; 2020 Nov; 24(11):634-644. PubMed ID: 32940573
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts.
Zhai X; Sun J; Yan Z; Zhang J; Zhao J; Zhao Z; Gao Q; He WT; Veit M; Su S
J Virol; 2020 Jul; 94(15):. PubMed ID: 32404529
[TBL] [Abstract][Full Text] [Related]
4. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
[TBL] [Abstract][Full Text] [Related]
5. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY
Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096
[TBL] [Abstract][Full Text] [Related]
6. A global treatments for coronaviruses including COVID-19.
Yousefi B; Valizadeh S; Ghaffari H; Vahedi A; Karbalaei M; Eslami M
J Cell Physiol; 2020 Dec; 235(12):9133-9142. PubMed ID: 32394467
[TBL] [Abstract][Full Text] [Related]
7. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 strategically mimics proteolytic activation of human ENaC.
Anand P; Puranik A; Aravamudan M; Venkatakrishnan AJ; Soundararajan V
Elife; 2020 May; 9():. PubMed ID: 32452762
[TBL] [Abstract][Full Text] [Related]
9. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 host tropism: An in silico analysis of the main cellular factors.
Rangel HR; Ortega JT; Maksoud S; Pujol FH; Serrano ML
Virus Res; 2020 Nov; 289():198154. PubMed ID: 32918944
[TBL] [Abstract][Full Text] [Related]
11. Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19.
Yang N; Shen HM
Int J Biol Sci; 2020; 16(10):1724-1731. PubMed ID: 32226290
[TBL] [Abstract][Full Text] [Related]
12. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2.
Liu Z; Xiao X; Wei X; Li J; Yang J; Tan H; Zhu J; Zhang Q; Wu J; Liu L
J Med Virol; 2020 Jun; 92(6):595-601. PubMed ID: 32100877
[TBL] [Abstract][Full Text] [Related]
13. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
Zhu Y; Yu D; Yan H; Chong H; He Y
J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
[TBL] [Abstract][Full Text] [Related]
14. Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection.
Krishna G; Pillai VS; Veettil MV
Eur J Pharmacol; 2020 Oct; 885():173450. PubMed ID: 32739174
[TBL] [Abstract][Full Text] [Related]
15. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
[TBL] [Abstract][Full Text] [Related]
16. Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery.
Sternberg A; McKee DL; Naujokat C
Curr Top Med Chem; 2020; 20(16):1423-1433. PubMed ID: 32416679
[TBL] [Abstract][Full Text] [Related]
17. The Novel Insight of SARS-CoV-2 Molecular Biology and Pathogenesis and Therapeutic Options.
Asghari A; Naseri M; Safari H; Saboory E; Parsamanesh N
DNA Cell Biol; 2020 Oct; 39(10):1741-1753. PubMed ID: 32716648
[TBL] [Abstract][Full Text] [Related]
18. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19.
Huang Y; Yang C; Xu XF; Xu W; Liu SW
Acta Pharmacol Sin; 2020 Sep; 41(9):1141-1149. PubMed ID: 32747721
[TBL] [Abstract][Full Text] [Related]
19. Coronavirus Disease 2019-COVID-19.
Dhama K; Khan S; Tiwari R; Sircar S; Bhat S; Malik YS; Singh KP; Chaicumpa W; Bonilla-Aldana DK; Rodriguez-Morales AJ
Clin Microbiol Rev; 2020 Sep; 33(4):. PubMed ID: 32580969
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2.
Mittal A; Manjunath K; Ranjan RK; Kaushik S; Kumar S; Verma V
PLoS Pathog; 2020 Aug; 16(8):e1008762. PubMed ID: 32822426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
